Intrinsiqq
Cabot Corporation logo

Cabot Corporation Quality Score

CBT

⊜ Compare
Quality53

Growth is the primary weakness (avg 0/100). Valuation is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
80/100
21.1x

20–25x range, moderate premium

Cash Flow Multiple
90/100
13.8x

Under 20x cash flow, well covered

Revenue Growth
0/100
-4.2%

Below 2%, essentially flat

Cash Flow Growth
0/100
-7.1%

Below 2%, essentially flat

Business Quality & Capital Allocation

Share Dilution
100/100
-8.6%

Shrinking >2%, active buybacks

Margin Trend
100/100
+4.6pp

Expanded 3+pp, strong improvement

Capital Structure
0/100
$1.02B

Net debt/FCF of 3.6x, high leverage

2022
$206M
$1.57B
2023
$238M
$1.40B
2024
$223M
$1.27B
2025
$258M
$1.26B
TTM
$250M
$1.27B
CashDebt
Return on Capital
60/100
10.8%

10–15%, respectable returns

Customize WeightsPremiumUpgrade

Cabot (CBT) quality: score, margins and returns

Cabot (CBT) scores 53/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 8 metrics each scored 0 to 100, on 13.6% operating margins and 10.8% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Cabot (CBT) a high-quality business?+

Cabot scores 53 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 13.6% operating margin and a 10.8% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Cabot's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from CBT's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Cabot scores well and where it falls behind.

What is Cabot's return on invested capital (ROIC)?+

Cabot earns about 10.8% on its invested capital, which is solid. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to CBT's margins and growth on this scorecard to judge durability.

How profitable is Cabot?+

Cabot runs an operating margin of about 13.6% and a net margin of about 5.2%. Revenue has grown at roughly 7.3% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 6 May 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Fiscal year ends Sep. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Miscellaneous Chemical Products · Pick stocks to compare with CBT

CompareIntrinsic value
ESIElement Solutions Inc.
$33.44-4.65%32
OECOrion S.A.
$5.87+6.73%24
WDFCWD-40 Company
$233.00+5.23%58
FULH.B. Fuller Co.
$52.57+4.74%47
CSWCSW Industrials Inc.
$295.35+5.67%50
ALNYAlnylam Pharmaceuticals Inc
$161.08+0.74%81
SMGScotts Miracle-Gro Co.
$67.19+8.72%39
BMRNBiomarin Pharmaceutical Inc.
$57.13+2.64%47

Held by ETFs

CBT is in 125 US ETFs. The largest of them, with CBT's weight in each:

Spot a number that looks wrong? Check it in CBT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CBT

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.